Morgan Stanley Centessa Pharmaceuticals PLC Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Morgan Stanley holds 2,937,467 shares of CNTA stock, worth $37.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,937,467

Previous 1,924,509 52.63%

Holding current value

$37.5 Million

Previous $32.2 Million 31.04%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$14.38 - $19.03 $14.6 Million - $19.3 Million	1,012,958 Added 52.63%	2,937,467 $42.2 Million
Q4 2024 Feb 14, 2025	BUY	$15.04 - $18.67 $8.19 Million - $10.2 Million	544,858 Added 39.49%	1,924,509 $32.2 Million
Q3 2024 May 14, 2025	SELL	$8.58 - $16.99 $5.75 Million - $11.4 Million	-670,741 Reduced 32.71%	1,379,651 $22.1 Million
Q3 2024 Nov 14, 2024	SELL	$8.58 - $16.99 $5.75 Million - $11.4 Million	-670,741 Reduced 32.71%	1,379,651 $22.1 Million
Q2 2024 May 14, 2025	BUY	$8.04 - $11.87 $1.01 Million - $1.49 Million	125,883 Added 6.54%	2,050,392 $18.5 Million
Q2 2024 Oct 17, 2024	SELL	$8.04 - $11.87 $699,262 - $1.03 Million	-86,973 Reduced 4.07%	2,050,392 $18.5 Million
Q2 2024 Aug 14, 2024	SELL	$8.04 - $11.87 $699,262 - $1.03 Million	-86,973 Reduced 4.07%	2,050,392 $18.5 Million
Q1 2024 Oct 17, 2024	BUY	$6.73 - $12.2 $585,328 - $1.06 Million	86,973 Added 4.24%	2,137,365 $24.2 Million
Q1 2024 Aug 16, 2024	BUY	$6.73 - $12.2 $6.21 Million - $11.3 Million	923,315 Added 76.05%	2,137,365 $24.2 Million
Q1 2024 May 15, 2024	BUY	$6.73 - $12.2 $6.21 Million - $11.3 Million	923,315 Added 76.05%	2,137,365 $24.2 Million
Q4 2023 Aug 16, 2024	SELL	$5.52 - $8.03 $4.62 Million - $6.72 Million	-836,342 Reduced 40.79%	1,214,050 $9.66 Million
Q4 2023 Feb 13, 2024	BUY	$5.52 - $8.03 $1.41 Million - $2.06 Million	256,099 Added 26.73%	1,214,050 $9.66 Million
Q3 2023 Nov 15, 2023	BUY	$6.01 - $8.24 $801,265 - $1.1 Million	133,322 Added 16.17%	957,951 $6.2 Million
Q2 2023 Aug 14, 2023	BUY	$3.68 - $6.9 $297,056 - $556,981	80,722 Added 10.85%	824,629 $5.1 Million
Q1 2023 May 15, 2023	BUY	$3.03 - $4.0 $1.3 Million - $1.72 Million	428,772 Added 136.06%	743,907 $2.86 Million
Q4 2022 Feb 14, 2023	BUY	$3.05 - $4.19 $910,855 - $1.25 Million	298,641 Added 1810.6%	315,135 $976,000
Q3 2022 Nov 14, 2022	SELL	$3.8 - $5.91 $90,326 - $140,480	-23,770 Reduced 59.04%	16,494 $67,000
Q2 2022 Oct 27, 2022	BUY	$3.18 - $9.85 $59,313 - $183,722	18,652 Added 86.3%	40,264 $196,000
Q2 2022 Aug 15, 2022	BUY	$3.18 - $9.85 $59,313 - $183,722	18,652 Added 86.3%	40,264 $196,000
Q1 2022 Oct 27, 2022	SELL	$7.45 - $11.59 $138,957 - $216,176	-18,652 Reduced 46.32%	21,612 $194,000
Q1 2022 May 13, 2022	BUY	$7.45 - $11.59 $56,076 - $87,237	7,527 Added 53.44%	21,612 $194,000
Q4 2021 Feb 14, 2022	BUY	$10.99 - $17.54 $70,940 - $113,220	6,455 Added 84.6%	14,085 $158,000
Q3 2021 Nov 15, 2021	BUY	$16.7 - $23.11 $127,421 - $176,329	7,630 New	7,630 $128,000

Others Institutions Holding CNTA

# of Institutions

142

Shares Held

124M

Call Options Held

163K

Put Options Held

816K

View Full List

About Centessa Pharmaceuticals plc

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $1.2B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

More about CNTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account